HC Wainwright Predicts Rezolute's Q1 Earnings (NASDAQ:RZLT)

Key Points

• HC Wainwright estimates that Rezolute, Inc. will report Q1 2026 earnings of ($0.27) per share, with a full-year estimate of ($1.20) EPS for 2026.
• Rezolute recently missed expectations, reporting Q3 earnings of ($0.26) per share, falling short of the consensus estimate of ($0.23).
• The stock has a Buy rating from HC Wainwright, with a price target of $14.00, and an average target price of $14.40 among analysts.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Rezolute in a note issued to investors on Thursday, September 18th. HC Wainwright analyst D. Tsao anticipates that the company will earn ($0.27) per share for the quarter. HC Wainwright has a "Buy" rating and a $14.00 price target on the stock. The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Rezolute's Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.32) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at ($1.20) EPS, FY2028 earnings at ($0.64) EPS and FY2029 earnings at ($0.46) EPS.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its quarterly earnings results on Wednesday, September 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.03).

Other equities analysts also recently issued reports about the stock. Guggenheim reissued a "buy" rating and issued a $15.00 price target on shares of Rezolute in a research note on Monday. Wedbush restated an "outperform" rating and issued a $12.00 price objective on shares of Rezolute in a report on Thursday. BTIG Research restated a "buy" rating and issued a $17.00 price objective on shares of Rezolute in a report on Thursday. Finally, Maxim Group upped their price objective on shares of Rezolute from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $14.50.

Rezolute Price Performance

RZLT stock traded up $0.44 during trading on Monday, reaching $8.14. The company had a trading volume of 1,082,567 shares, compared to its average volume of 1,179,967. Rezolute has a 52 week low of $2.21 and a 52 week high of $8.81. The business has a 50 day moving average of $6.62 and a 200 day moving average of $4.74.

Institutional Investors Weigh In On Rezolute

A number of institutional investors have recently made changes to their positions in the company. Federated Hermes Inc. grew its holdings in shares of Rezolute by 24.4% during the second quarter. Federated Hermes Inc. now owns 14,034,712 shares of the company's stock valued at $62,595,000 after buying an additional 2,755,385 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Rezolute by 56.4% during the second quarter. Marshall Wace LLP now owns 2,886,481 shares of the company's stock valued at $12,874,000 after buying an additional 1,041,234 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Rezolute by 77.4% during the second quarter. Nantahala Capital Management LLC now owns 2,291,395 shares of the company's stock valued at $10,220,000 after buying an additional 1,000,000 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Rezolute by 29.4% during the second quarter. Affinity Asset Advisors LLC now owns 2,200,000 shares of the company's stock valued at $9,812,000 after buying an additional 500,000 shares during the last quarter. Finally, Rosalind Advisors Inc. purchased a new stake in shares of Rezolute during the second quarter valued at approximately $7,766,000. Hedge funds and other institutional investors own 82.97% of the company's stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.